BridgeBio Pharma Inc vs Google Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.36B), while Google Inc trades at $344.78 (market cap $4.20T). The key difference: Google Inc is far larger — about 256.7× BridgeBio Pharma Inc's market cap, and Google Inc pays a 0.26% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | GOOG | |
|---|---|---|
Market Cap | $16.36B | $4.20T |
Sector | Health | Technology |
52-Week High | $90.17 | $399.06 |
52-Week Low | $47.29 | $200.19 |
Enterprise Value | $18.14B | $4.09T |
Volume | — | 1,511,127 |
Dividend Yield | — | 0.26% |
Trailing returns across standard periods
Latest headlines on both assets
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →